Postsynaptic density: A key convergent site for schizophrenia susceptibility factors and possible target for drug development

Ryota Hashimoto, Stephanie Tankou, Masatoshi Takeda, Akira Sawa

Research output: Contribution to journalArticle

Abstract

Many studies have supported roles for both genetic and environmental factors in the etiology of schizophrenia. A major hypothesis at present is that schizophrenia is a polygenic disorder where alterations in a set of genes lead to impaired neurodevelopment, which in turn results in altered neurotransmission. Several neurotransmitters, including glutamate, dopamine, serotonin and gamma-amino butyric acid (GABA), have been implicated in schizophrenia, and, as such, there is a growing interest in trying to elucidate the mechanisms whereby alterations in the function of schizophrenia susceptibility gene products can lead to disturbance in signaling at synapses. In this article, we will summarize what is known about schizophrenia susceptibility factors that reside at postsynaptic density (PSD), a unique postsynaptic site where signals from neurotransmitters converge. PSD may be a promising target for novel classes of drugs to treat schizophrenia.

Original languageEnglish (US)
Pages (from-to)645-654
Number of pages10
JournalDrugs of Today
Volume43
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Post-Synaptic Density
Schizophrenia
Pharmaceutical Preparations
Neurotransmitter Agents
Butyric Acid
Synaptic Transmission
Synapses
Genes
Glutamic Acid
Dopamine
Serotonin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Postsynaptic density : A key convergent site for schizophrenia susceptibility factors and possible target for drug development. / Hashimoto, Ryota; Tankou, Stephanie; Takeda, Masatoshi; Sawa, Akira.

In: Drugs of Today, Vol. 43, No. 9, 09.2007, p. 645-654.

Research output: Contribution to journalArticle

Hashimoto, Ryota ; Tankou, Stephanie ; Takeda, Masatoshi ; Sawa, Akira. / Postsynaptic density : A key convergent site for schizophrenia susceptibility factors and possible target for drug development. In: Drugs of Today. 2007 ; Vol. 43, No. 9. pp. 645-654.
@article{0cfc4886967f48dcbbbd22e3f603f9cc,
title = "Postsynaptic density: A key convergent site for schizophrenia susceptibility factors and possible target for drug development",
abstract = "Many studies have supported roles for both genetic and environmental factors in the etiology of schizophrenia. A major hypothesis at present is that schizophrenia is a polygenic disorder where alterations in a set of genes lead to impaired neurodevelopment, which in turn results in altered neurotransmission. Several neurotransmitters, including glutamate, dopamine, serotonin and gamma-amino butyric acid (GABA), have been implicated in schizophrenia, and, as such, there is a growing interest in trying to elucidate the mechanisms whereby alterations in the function of schizophrenia susceptibility gene products can lead to disturbance in signaling at synapses. In this article, we will summarize what is known about schizophrenia susceptibility factors that reside at postsynaptic density (PSD), a unique postsynaptic site where signals from neurotransmitters converge. PSD may be a promising target for novel classes of drugs to treat schizophrenia.",
author = "Ryota Hashimoto and Stephanie Tankou and Masatoshi Takeda and Akira Sawa",
year = "2007",
month = "9",
doi = "10.1358/dot.2007.43.9.1088821",
language = "English (US)",
volume = "43",
pages = "645--654",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Postsynaptic density

T2 - A key convergent site for schizophrenia susceptibility factors and possible target for drug development

AU - Hashimoto, Ryota

AU - Tankou, Stephanie

AU - Takeda, Masatoshi

AU - Sawa, Akira

PY - 2007/9

Y1 - 2007/9

N2 - Many studies have supported roles for both genetic and environmental factors in the etiology of schizophrenia. A major hypothesis at present is that schizophrenia is a polygenic disorder where alterations in a set of genes lead to impaired neurodevelopment, which in turn results in altered neurotransmission. Several neurotransmitters, including glutamate, dopamine, serotonin and gamma-amino butyric acid (GABA), have been implicated in schizophrenia, and, as such, there is a growing interest in trying to elucidate the mechanisms whereby alterations in the function of schizophrenia susceptibility gene products can lead to disturbance in signaling at synapses. In this article, we will summarize what is known about schizophrenia susceptibility factors that reside at postsynaptic density (PSD), a unique postsynaptic site where signals from neurotransmitters converge. PSD may be a promising target for novel classes of drugs to treat schizophrenia.

AB - Many studies have supported roles for both genetic and environmental factors in the etiology of schizophrenia. A major hypothesis at present is that schizophrenia is a polygenic disorder where alterations in a set of genes lead to impaired neurodevelopment, which in turn results in altered neurotransmission. Several neurotransmitters, including glutamate, dopamine, serotonin and gamma-amino butyric acid (GABA), have been implicated in schizophrenia, and, as such, there is a growing interest in trying to elucidate the mechanisms whereby alterations in the function of schizophrenia susceptibility gene products can lead to disturbance in signaling at synapses. In this article, we will summarize what is known about schizophrenia susceptibility factors that reside at postsynaptic density (PSD), a unique postsynaptic site where signals from neurotransmitters converge. PSD may be a promising target for novel classes of drugs to treat schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=35548973985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548973985&partnerID=8YFLogxK

U2 - 10.1358/dot.2007.43.9.1088821

DO - 10.1358/dot.2007.43.9.1088821

M3 - Article

C2 - 17940640

AN - SCOPUS:35548973985

VL - 43

SP - 645

EP - 654

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 9

ER -